Literature DB >> 15885880

Prolactin signals via Stat5 and Oct-1 to the proximal cyclin D1 promoter.

Jennifer L Brockman1, Linda A Schuler.   

Abstract

Prolactin (PRL) modulates proliferation in the mammary gland and other tissues, in part through inducing transcription of cyclin D1, a key regulator of G(1) phase cell cycle progression. We showed previously that PRL, via Jak2, induces binding of Stat5 to a distal GAS site (GAS1) in the cyclin D1 promoter. However, full promoter activity requires additional regions, and in this paper we explored PRL-induced activity at sites other than GAS1. We defined a second PRL-responsive region spanning -254 to -180 that contains a second GAS site (GAS2) and an Oct-1 binding site. Although mutational analysis indicated independence from GAS2, proximal promoter activity remained Stat5-dependent, suggesting alternative mechanisms. EMSA showed that Oct-1 binds the -254 to -180 region and that PRL decreased Oct-1 binding, leading to increased PRL-responsiveness of the proximal cyclin D1 promoter in multiple cell lines. This suggests a role for Oct-1 in PRL-dependent control of cyclin D1 transcription.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885880      PMCID: PMC1635012          DOI: 10.1016/j.mce.2005.04.006

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  33 in total

Review 1.  The virtuoso of versatility: POU proteins that flex to fit.

Authors:  K Phillips; B Luisi
Journal:  J Mol Biol       Date:  2000-10-06       Impact factor: 5.469

Review 2.  Mammary gland development in prolactin receptor knockout mice.

Authors:  C J Ormandy; N Binart; P A Kelly
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

3.  PRL activates the cyclin D1 promoter via the Jak2/Stat pathway.

Authors:  Jennifer L Brockman; Matthew D Schroeder; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2002-04

Review 4.  Signal transduction and the control of gene expression.

Authors:  Ali H Brivanlou; James E Darnell
Journal:  Science       Date:  2002-02-01       Impact factor: 47.728

Review 5.  A specific role for cyclin D1 in mammary gland development.

Authors:  P Sicinski; R A Weinberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  1997-10       Impact factor: 2.673

Review 6.  Prolactin: the new biology of an old hormone.

Authors:  Vincent Goffin; Nadine Binart; Philippe Touraine; Paul A Kelly
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

7.  Stat5b inhibits NFkappaB-mediated signaling.

Authors:  G Luo; L Yu-Lee
Journal:  Mol Endocrinol       Date:  2000-01

8.  Functional characterization of the intermediate isoform of the human prolactin receptor.

Authors:  J B Kline; H Roehrs; C V Clevenger
Journal:  J Biol Chem       Date:  1999-12-10       Impact factor: 5.157

Review 9.  Prolactin: structure, function, and regulation of secretion.

Authors:  M E Freeman; B Kanyicska; A Lerant; G Nagy
Journal:  Physiol Rev       Date:  2000-10       Impact factor: 37.312

10.  Different mechanisms for leukemia inhibitory factor-dependent activation of two proopiomelanocortin promoter regions.

Authors:  Vanessa Mynard; Laurence Guignat; Jocelyne Devin-Leclerc; Xavier Bertagna; Maria Grazia Catelli
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

View more
  26 in total

1.  Cyclophilin B as a co-regulator of prolactin-induced gene expression and function in breast cancer cells.

Authors:  Feng Fang; Jiamao Zheng; Traci L Galbaugh; Alyson A Fiorillo; Elizabeth E Hjort; Xianke Zeng; Charles V Clevenger
Journal:  J Mol Endocrinol       Date:  2010-03-17       Impact factor: 5.098

Review 2.  The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks.

Authors:  Karina Vázquez-Arreguín; Dean Tantin
Journal:  Biochim Biophys Acta       Date:  2016-02-10

Review 3.  The biological functions of the versatile transcription factors STAT3 and STAT5 and new strategies for their targeted inhibition.

Authors:  Sylvane Desrivières; Christian Kunz; Itamar Barash; Vida Vafaizadeh; Corina Borghouts; Bernd Groner
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

4.  Cyclin D3 compensates for the loss of cyclin D1 during ErbB2-induced mammary tumor initiation and progression.

Authors:  Qian Zhang; Kazuhito Sakamoto; Chengbao Liu; Aleata A Triplett; Wan-chi Lin; Hallgeir Rui; Kay-Uwe Wagner
Journal:  Cancer Res       Date:  2011-10-28       Impact factor: 12.701

Review 5.  Crosstalk between STAT5 activation and PI3K/AKT functions in normal and transformed mammary epithelial cells.

Authors:  Patrick D Rädler; Barbara L Wehde; Kay-Uwe Wagner
Journal:  Mol Cell Endocrinol       Date:  2017-05-08       Impact factor: 4.102

6.  Role of ERalpha in the differential response of Stat5a loss in susceptibility to mammary preneoplasia and DMBA-induced carcinogenesis.

Authors:  Anne M Miermont; Angela R Parrish; Priscilla A Furth
Journal:  Carcinogenesis       Date:  2010-02-24       Impact factor: 4.944

7.  Involvement of the ubiquitous Oct-1 transcription factor in hormonal induction of beta-casein gene expression.

Authors:  Bing Dong; Feng-Qi Zhao
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

8.  Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.

Authors:  K Sakamoto; A A Triplett; L A Schuler; K-U Wagner
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

9.  Autocrine prolactin: an emerging market for homegrown (prolactin) despite the imports.

Authors:  Senthil K Muthuswamy
Journal:  Genes Dev       Date:  2012-10-15       Impact factor: 11.361

10.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.